Loargys (pegzilarginase-nbln) is indicated for the treatment of Arginase 1 Deficiency (ARG1-D), also known as hyperargininemia, in adult and pediatric patients 2 years of age and older, a rare urea cycle disorder characterized by elevated plasma arginine levels and progressive neurological impairment.
Loargys functions as an enzyme replacement therapy, reducing toxic arginine accumulation and helping to manage the metabolic and neurological complications associated with the disease.
